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problems with a cable. In both events, the LVAS worked nor-
mally and the patient’s condition was stable. The cable was
thoroughly examined and repaired by a technician from TCI.
Four days after the second cable repair, the red alarm suddenly
warned at home. The manual mechanical pumping with the
hand pump was immediately initiated by the patient himself,
and he was transferred to our hospital urgently by helicopter.
During the transport his condition worsened and he needed to
be intubated. This emergency occurred 380 days after the
LVAS implantation. The LVAS could still work with the pneu-
matic system, so that his hemodynamic condition was well
controlled with dopamine perfusion. The problem with the
LVAS was studied by a technician from TCI. Because dried
bloodlike material was observed in the hand pump and the
stroke volume limiter connecting tube, we suspected a rupture
of the drive line or the diaphragm separating the blood pump
chamber from the motor chamber in the LVAS. We exchanged
the LVAS through the incision in the abdominal pocket with
cardiopulmonary bypass established through the femoral artery
and vein. The postoperative course was excellent. He was dis-
charged to his home on postoperative day 24 and is now wait-
ing for heart transplantation. The explanted pump was careful-
ly examined. The motor chamber was filled with clotted dried
blood, which prevented the motor/cam assembly from working
(Fig 1). However, by macroscopic observation we could not
find any tears or holes in the diaphragm. The pump was sent
to TCI for precise inspection. TCI’s technicians detected small
tears at the rim of the diaphragm, which might have been
caused by mechanical fatigue. 
The TCI HeartMate LVAS is one of the most reliable sys-
tems in the world.1,2 We have implanted the pneumatic
HeartMate LVAS in 14 patients since April 1994 and the VE
HeartMate LVAS in 28 patients since November 1995.3 A
similar device disorder with the VE HeartMate LVAS was
reported by Piccione and colleagues4 in 1998. They showed,
as in this report, that the motor chamber filled with clotted
blood. However, they could not find any perforation on the
drive line, and they did not refer to the diaphragm. To our
knowledge, this is the first report of a disorder of the
diaphragm in the pump with the VE HeartMate LVAS. The
support time of this patient was 380 days. This long support
time might be one of the reasons for this defect. 
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A word of caution in extrapolating the spinal cord
protective effects of memantine obtained in a rabbit
model under ketamine anesthesia
To the Editor:
We read with great interest the article titled “Memantine
for Prevention of Spinal Cord Injury in a Rabbit Model” by
Ehrlich and associates (J Thorac Cardiovasc Surg 1999;117:
285-91). We do not doubt the protective effects exhibited by
memantine, a noncompetitive N-methyl-D-aspartate (NMDA)
receptor antagonist, and we believe it is a significant contri-
bution to central nervous system protection.
However, we would like to bring a few points to the atten-
tion of the readership:
1. The protective effects of NMDA antagonists are widely
known.1 Part of that protection is due to the hypothermic
effect of NMDA antagonists.2 In any study to assess protec-
tion, specifying only the ischemic time is not enough; speci-
fying the temperature as well, preferably the esophageal tem-
perature, is almost mandatory.
2. The temperature was monitored rectally and, although a
heating pad was used to maintain normal body temperature,
it would have been informative to specify the temperature
itself. We have found that esophageal temperatures more
closely reflect spinal cord temperatures than do rectal tem-
peratures.3 Rectal temperatures are usually higher than
esophageal temperatures, sometimes by as much as 0.5°C to
1.2°C, and esophageal temperature differences as small as
0.5°C might result in totally different neurologic outcomes.2,3
3. Their anesthesia protocol included ketamine, which
resulted in instant loss of transcranial motor-evoked poten-
tials. This can be explained on the basis of the known NMDA
receptor antagonism of ketamine, which is responsible for the
reported protective effects.1,4 Thus the observed protective
effects of memantine were the result of the effects of meman-
tine by itself in addition to those contributed by ketamine, but
their relative roles are unknown. For definitive assessment of
the protective effects of memantine alone, a group of rabbits
anesthetized with nonprotective concentrations of volatile
agents without ketamine or barbiturates is essential before the
data can be extrapolated to human application, because keta-
mine is no longer widely used in humans.
4. Obviously, slow intravenous infusion of memantine over
a 30-minute period before ischemia resulted in better protec-
tion than a fast (3-minute) intra-arterial infusion into the aorta
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distal to the aortic crossclamp, that is, after ischemia. The dif-
ferent results are probably related to how fast the memantine
can cross the blood-brain barrier. Had the intra-arterial infu-
sion been performed over a 30-minute period before aortic
crossclamping, which of course is impractical, the results
might have been different. We have found that a 20- to 30-
minute period is usually necessary for effects of pharmaco-
logic agents (including those of adenosine and adenosine
triphosphate) to significantly appear in the brain interstitial
fluid after intravenous administration (bolus or infusion).
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Reply to the Editor:
My colleagues and I thank Miyamoto and Miyamoto for
their interest and comments on our recent article regarding
the N-methyl-D-aspartate (NMDA) blocker memantine.1
As we are aware of the protective effect of hypothermia on
the release of excitatory amino acids, we have tried to keep the
rectal temperature in a normothermic range assuming that the
rectal temperature will reflect more accurate spinal cord tem-
perature than esophageal temperature. However, we will addi-
tionally monitor esophageal temperature in future experiments.
With respect to our anesthesia protocol, a comparable
experiment investigating the influence of anesthetics on neu-
rologic recovery showed that ketamine treatment reduced
acute paraplegia but increased delayed paraplegia.2 In our
study, the control group did not show a protective effect of
ketamine compared with the groups treated with memantine.
Volatile anesthetics and nitrous oxide are suppressive to myo-
genic motor-evoked responses,3 but ketamine is recommend-
ed as a suitable supplement to opioid/nitrous oxide anesthe-
sia in men.4 In our experiments we used ketamine to keep the
experimental conditions constant and to avoid false positive
depression of motor-evoked potentials due to the influence of
an anesthetic.
In regard to the different applications of memantine, we
assumed that intra-arterial infusion of memantine into the
clamped aortic segment would result in better protection than
administering the drug systematically. We were surprised by
the fact that the systemic group did better than the intra-aor-
tic group. We concur that this phenomenon was due to the
slow crossing of memantine through the blood-brain barrier.
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Possible mechanism of calcification of the BioCor
stentless mitral valve treated with the No-React
formula
To the Editor:
I read with great interest the brief communication by Milo
and associates regarding the possible mechanism of calcifica-
tion of the BioCor stentless mitral valve (BioCor,
Belohorizonte, Brazil) treated with the No-React anticalcifi-
cation formula (Shelhigh Inc, Millburn, NJ) in 2 adolescents. 
These 2 children were 13 years old at time of implantation.
Both had mitral and aortic endocarditis. Both needed double
valve replacement. I assume anticoagulation was not an
option. Milo and associates elected to implant the BioCor
stentless aortic and mitral valves treated with No-React anti-
calcification formula in both children. The BioCor mitral
valve was a newly designed porcine mitral valve specially fit-
ted to be implanted in the mitral position. Milo and col-
leagues can be congratulated for the proficient implantations
of the double valves in both children. 
Mechanism of calcification. Once a valve is inflamed or
infected, calcification will occur in a few months or a few
years. Furthermore, nonmoving cusps tend to calcify early.
The BioCor stentless mitral valve is still an experimental
valve design (Fig 1). The major drawback is the length limi-
tations of the chordae. If the patient has a large heart, the
chordae will be too short. This mismatch of chordal length
can cause extra tension and rupture of the chordae. Further-
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